Rectify Pharmaceuticals has never run a human trial before, and now it is recruiting an executive chairman with a track record of selling hepatobiliary companies to large acquirers. That sequencing is deliberate. Constantine Chinoporos joins the Cambridge biotech effective immediately, stepping into the role just as RTY-406 moves through its Phase 1 study in primary sclerosing cholangitis, a progressive bile duct disease where approved options remain limited and long-term management has relied on off-label approaches including ursodeoxycholic acid and liver transplantation for advanced cases.
The credentials Chinoporos brings are specific to this disease and this moment. He served as Chief Business Officer at Albireo Pharmaceuticals through its $952 million acquisition by Ipsen in 2023, a deal built on pediatric cholestatic liver disease assets. He then moved to Applied Therapeutics, which was acquired by Cycle Group Holdings in February 2026. That is two exits in three years, both in rare disease, which tells you something about what Rectify’s board is optimizing for beyond just clinical execution. Adding someone with that resume at the executive chairman level is not a governance formality.
RTY-406 is the scientific bet underneath all of this. The molecule is an orally administered dual modulator of ABCB4 and BSEP, two membrane transporters whose dysfunction drives abnormal bile composition and impaired bile flow in PSC. Targeting both simultaneously is the mechanism that distinguishes it from prior attempts in this space, and preclinical data presented at EASL 2026 showed improvements across inflammation, cholangitis, cholestasis, and fibrosis endpoints in a mouse model of PSC with additional proof-of-mechanism data in non-human primates. The company’s broader platform, which it calls Positive Functional Modulators, also anchors a research and licensing agreement with Boehringer Ingelheim focused on chronic kidney disease, giving Rectify a second validation point for the underlying science without diluting the PSC narrative.
The single outcome to track from here is whether RTY-406 generates measurable biomarker movement in Phase 1, specifically alkaline phosphatase reduction, which has served as a surrogate signal of bile duct injury in PSC clinical programs. A clean early signal on that marker would shift Rectify from an intriguing platform story into a genuine acquisition target, and Chinoporos has done exactly that job twice before.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
